日本語 
TherapiAI a company based in Taiwan that creates intelligence solutions for the pharmaceutical industry presented its Biopharma AI Operating Layer at BioJapan 2026 in Yokohama. The event took place from October 7 to 9. The company wants to grow its presence in Japan. It wants to help pharmaceutical companies and CDMOs bring AI into their research quality management, regulatory documentation and manufacturing processes.
This announcement shows that the life sciences industry is focusing more on using AI beyond small projects. They want to use AI in systems that can work with current processes, security measures and rules.
AI Agents Focus on Research and Regulatory Processes
TherapiAIs platform has AI agents and tools to manage them. Two important uses are Omnik-BIOS, which’s for research and development of biologics and protein medicines and Omnik-QD which helps quality and regulatory teams.
Omnik-BIOS helps with looking at protein sequences, three- shapes changes after production how the body reacts and how easy it is to develop. These checks can help researchers find problems early. However the analysis done by AI still needs to be checked by scientists.
Omnik-QD helps with comparing documents finding parts writing drafts and searching through company information. These tasks are common in the pharmaceutical industry. Teams need to look at a lot of documents and make sure everything is the same, in quality and regulatory work.
Enterprise Controls Remain Central to Adoption
The Biopharma AI Operating Layer also contains a management platform that helps deploy and coordinate AI agents. TherapiAI says it works with private‑cloud and on‑premises setups and can link to existing quality management systems, laboratory information management systems and manufacturing execution systems.
I notice that these integration features solve a problem for pharma companies. Research data, operating procedures, lab records and production documents are often spread over many different systems.
Before AI agents can read data or run tasks companies must set up data permissions, audit trails, output checks and human‑review steps. These rules matter especially in settings because wrong data or undocumented actions can hurt product quality and compliance.
TherapiAI says this approach lets companies start with one AI agent and then add more to departments without overhauling their current IT infrastructure all, at once.
BioJapan Generates Interest From Japanese Companies
During the three-day event, TherapiAI reported meeting with at least 113 companies from seven countries. The company said 16 biopharmaceutical CDMOs expressed interest in trialling the platform or collaborating on Pharma 4.0 initiatives, while 41 Japanese pharmaceutical companies requested follow-up meetings.
According to the company, discussions frequently focused on whether the technology could work with existing quality, laboratory and document systems, as well as how AI outputs could be checked and reviewed.
Following BioJapan, TherapiAI plans to pursue technical evaluations with interested organizations and seek local distributors, consulting firms and system integration partners in Japan. The company previously announced a partnership with Japanese AI scientific computing startup Chiral in April 2026 and signed a memorandum of understanding with digital manufacturing solutions provider LSDC in May.
Also Read: SCSK Develops AI Sales Agent With Salesforce Agentforce
The implications for Japan’s biopharmaceutical industry are significant. The platform’s presentation shows a trend in pharmaceutical technology—moving toward AI-assisted workflows that cover research, development, quality assurance and manufacturing.
For pharmaceutical companies and contract development and manufacturing organizations specialized AI agents could offer real benefits. These agents could cut down on document tasks help organize complicated scientific data and improve coordination between departments.. The actual value depends on several factors. Data quality must be high. The AI systems need to connect with existing tools and processes. Validation steps must be clear and reliable.. All of this must meet regulatory and compliance standards that are strict in the industry.
The next phase for TherapiAI, in Japan will focus on turning interest from customers into technical evaluations and real-world deployments. How these evaluations go will be key. They will show how well agentic AI can work within pharmaceutical processes. They will also test whether AI can deliver results while still allowing the oversight that the industry demands.
English